"Obesity and Type 2 diabetes have reached epidemic proportions, and the healthcare community is struggling to find new ways to improve the treatment of these devastating and often fatal diseases. The immediate and sustained reduction in HbA1c levels observed with EndoBarrier in this controlled clinical trial equal or exceed the glycemic control produced by leading pharmaceutical treatments."

— Lee Kaplan, MD, PhD, associate professor of medicine at Harvard Medical School, extolling the virtues of the EndoBarrier, which its maker, GI Dynamics, claims is able to improve glycemic control in diabetics independently of weight loss, "EndoBarrier GI liner data shows promise for diabetes and obesity."